Search Result

Results for "

Arterial thrombosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Metabolite (1) Endogenous Metabolite (3) Factor Xa (3) Factor XI (1) HIF/HIF Prolyl-Hydroxylase (2) Integrin (4) Kallikrein (1) P2Y Receptor (1) Prostaglandin Receptor (2) Ser/Thr Protease (1) Thrombin (7)
By Research Areas:	Cancer (3) Cardiovascular Disease (22) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Nucleotide Analogs (1) Aptamers (4) Adenine Nucleotide (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2299

Morusinol	Others	Cardiovascular Disease
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo .

HY-D0199

Adenosine 5'-diphosphate disodium 5 Publications Verification	Endogenous Metabolite	Cardiovascular Disease
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-124124

N-Methylnicotinamide 1 Publications Verification	Endogenous Metabolite Drug Metabolite	Cardiovascular Disease Metabolic Disease Cancer
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway. N-Methylnicotinamide is a potential biomarker in miR-1291-altered pancreatic cell metabolism and tumorigenesis .

HY-19219A

BMS-189664 hydrochloride	Thrombin	Cardiovascular Disease
BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research .

HY-19219

BMS-189664	Thrombin	Cardiovascular Disease
BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research .

HY-P2021

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-D0199R

Adenosine 5'-diphosphate disodium (Standard)	Endogenous Metabolite	Cardiovascular Disease
Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-11090A

DPC423	Factor Xa Kallikrein Thrombin Ser/Thr Protease	Cardiovascular Disease
DPC423 is a selective and orally active factor Xa inhibitor with a K_is of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits K_is of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 has demonstrated antithrombotic effects in animal models, and when used in combination with Aspirin (HY-14654), it shows a strong synergistic effect. DPC423 can be used for the study of anticoagulation of arterial thrombosis .

HY-153998

BT100 sodium	Integrin	Cardiovascular Disease
BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-10270

Flovagatran TGN 255	Thrombin	Cardiovascular Disease
Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis .

HY-10271

Flovagatran sodium TGN 255 sodium	Thrombin	Cardiovascular Disease
Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis .

HY-19229

TAK-029	Integrin	Cardiovascular Disease
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .

HY-153999

Rondaptivon pegol BT200	Integrin	Cardiovascular Disease
Rondaptivon pegol (BT200), a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153999A

Rondaptivon pegol sodium BT200 sodium	Integrin	Cardiovascular Disease
Rondaptivon pegol (BT200) sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-117561

DuP 714	Thrombin	Cardiovascular Disease
DuP 714 is an oral active thrombin inhibitor with the IC₅₀ values of 150 nM aganist thrombin-induced aggregation in washed human platelets. DuP 714 can be used for study of arterial thrombosi .

HY-15468A

IOX2 sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
IOX2 sodium is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC₅₀ of 22 nM. IOX2 sodium regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 sodium can be used in the study of thrombotic diseases .

HY-15468

IOX2 Maximum Cited Publications 17 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
IOX2, a chemical probe, is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC₅₀ of 22 nM. IOX2 regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 can be used in the study of thrombotic diseases .

HY-19249

Z-335 sodium	Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Z-335 sodium is an orally active thromboxane a₂ (TXA₂) receptor antagonist, with IC₅₀ values of 29.9 nM and 32.5 nM for human and Guinea pig platelets, respectively .

HY-123400A

iso-Samixogrel iso-DTTX30; iso-DT-TX 30 SE	Prostaglandin Receptor	Cardiovascular Disease
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.

HY-172400

FXIa-IN-16	Factor XI	Cardiovascular Disease
FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC₅₀ of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis .

HY-10267

Eribaxaban PD-0348292	Factor Xa	Cardiovascular Disease
Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a K_i value of 0.32 nM. Eribaxaban reduces thrombus formation .

HY-162164

Neuroprotective agent 3	Others	Neurological Disease
Neuroprotective agent 3 (Compound 21a) is an antioxidant that exhibits neuroprotective effects. Neuroprotective agent 3 significantly increases neuronal viability and induces neuroprotection, as well as improves neurological deficit scores in an in vivo model of transient cerebral ischemia .

HY-108658

MRS2500 tetraammonium	P2Y Receptor	Cardiovascular Disease
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC₅₀ value of 0.95 nM. Antithrombotic activity .

Cat. No.	Product Name	Type

HY-D0199

Adenosine 5'-diphosphate disodium 5 Publications Verification	Biochemical Assay Reagents
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-D0199R

Adenosine 5'-diphosphate disodium (Standard)	Biochemical Assay Reagents
Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

Adenosine 5'-diphosphate disodium (Standard)

Biochemical Assay Reagents

Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

Morusinol	Cardiovascular Disease Flavonoids Classification of Application Fields Flavones Source classification Phenols Polyphenols Plants Moraceae Disease Research Fields Morus alba Linn.	Others
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo .

N-Methylnicotinamide 1 Publications Verification	Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway. N-Methylnicotinamide is a potential biomarker in miR-1291-altered pancreatic cell metabolism and tumorigenesis .

Adenosine 5'-diphosphate disodium (Standard)	Natural Products Source classification Endogenous metabolite	Endogenous Metabolite
Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

Cat. No.	Product Name		Classification

HY-D0199

Adenosine 5'-diphosphate disodium 5 Publications Verification		Nucleotide Analogs Adenine Nucleotide
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-153999

Rondaptivon pegol BT200		Aptamers
Rondaptivon pegol (BT200), a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153999A

Rondaptivon pegol sodium BT200 sodium		Aptamers
Rondaptivon pegol (BT200) sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-156501

BT101 sodium		Aptamers
BT101 (sodium), a complementary aptamer, has been developed to specifically inhibit BT100 function. BT100, a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153998

BT100 sodium		Aptamers
BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Arterial thrombosis

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Oligonucleotides

Natural
Products